Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Ashish M. Kamat; Thomas W. Flaig; H. Barton Grossman; Badrinath Konety; Donald Lamm; Michael A. O'Donnell; Edward Uchio; Jason A. Efstathiou; John A. Taylor

doi:10.1038/nrurol.2015.58

Back

Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Journal article

Open access

Peer reviewed

Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Ashish M. Kamat, Thomas W. Flaig, H. Barton Grossman, Badrinath Konety, Donald Lamm, Michael A. O'Donnell, Edward Uchio, Jason A. Efstathiou and John A. Taylor

Nature reviews. Urology, Vol.12(4), pp.225-235

04/01/2015

DOI: 10.1038/nrurol.2015.58

PMID: 25800393

Files and links (1)

url

https://doi.org/10.1038/nrurol.2015.58View

Published (Version of record) Open Access

Abstract

Multiple clinical trials have demonstrated that intravesical Bacillus Calmette-Guerin (BCG) treatment reduces recurrences and progression in patients with non-muscle-invasive bladder cancer (NMIBC). However, although BCG has been in use for almost 40 years, this agent is often underutilized and practice patterns of administration vary. This neglect is most likely caused by uncertainties about the optimal use of BCG, including unawareness of optimal treatment schedules and about patient populations that most benefit from BCG treatment. To address this deficit, a focus group of specialized urologic oncologists (urologists, medical oncologists and radiation oncologists) reviewed the current guidelines and clinical evidence, discussed their experiences and formed a consensus regarding the optimal use of BCG in the management of patients with NIMBC. The experts concluded that continuing therapy with 3-week BCG maintenance is superior to induction treatment only and is the single most important factor in improving outcomes in patients with NMIBC. They also concluded that a reliable alternative to radical cystectomy in truly BCG-refractory disease remains the subject of clinical trials. In addition, definitions for common terms of BCG failure, such as BCG-refractory and BCG-intolerant, have been formulated.

Life Sciences & Biomedicine

Science & Technology

Urology & Nephrology

Details

Title: Subtitle: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
Creators: Ashish M. Kamat - Urology
Thomas W. Flaig - University of Colorado System
H. Barton Grossman - The University of Texas MD Anderson Cancer Center
Badrinath Konety - University of Minnesota
Donald Lamm - NRG Oncology
Michael A. O'Donnell - Univ Iowa, Iowa City, IA 52242 USA
Edward Uchio - University of California, Irvine
Jason A. Efstathiou - Harvard University
John A. Taylor - University of Connecticut
Resource Type: Journal article
Publication Details: Nature reviews. Urology, Vol.12(4), pp.225-235
DOI: 10.1038/nrurol.2015.58
PMID: 25800393
NLM abbreviation: Nat Rev Urol
ISSN: 1759-4812
eISSN: 1759-4820
Publisher: NATURE PORTFOLIO
Number of pages: 11
Language: English
Date published: 04/01/2015
Academic Unit: Urology
Record Identifier: 9984320859102771

Metrics

4 Record Views

155 Times Cited - Web of Science

See more details